Patent Application Strategy in Europe for the Pharmaceutical Industry - How should pharmaceutical companies’ patent application strategy change with the introduction of the Unitary Patent and the European and European Union Patent Court?
(2012) HARH10 20112Department of Business Law
- Abstract
- This thesis aims to establish how the introduction of the Unitary Patent and the European and European Union Patent Court will affect the pharmaceutical industry’s choice of patent application route when applying for patents in Europe in the future. To establish the expected effect of the Unitary Patent on the industry interviews with a selection of professionals in the research and development industry, the public sector and a patent litigator have been carried out. The research and interviews has shown an array of advantages associated with the Unitary Patent, mainly of economic nature as an effect of reduced translation requirements and increased centralised administration but also we are likely to see that practice will eventually... (More)
- This thesis aims to establish how the introduction of the Unitary Patent and the European and European Union Patent Court will affect the pharmaceutical industry’s choice of patent application route when applying for patents in Europe in the future. To establish the expected effect of the Unitary Patent on the industry interviews with a selection of professionals in the research and development industry, the public sector and a patent litigator have been carried out. The research and interviews has shown an array of advantages associated with the Unitary Patent, mainly of economic nature as an effect of reduced translation requirements and increased centralised administration but also we are likely to see that practice will eventually become more predictable within Europe. Many of the problems that remain to be established in the draft agreements have proven to be a major disadvantage to the Unitary Patent as it adds a dimension of uncertainty to the patent holder. The fact that Italy and Spain have chosen to opt out of the Unitary Patent project is unsurprisingly a major disadvantage to the project and the European Union as a whole. It has been concluded that the many uncertainties and the disadvantages already shown with the Unitary Patent the best recommendation to patent applicants in the future is to stay with the European patent or national patents to see how European and European Union Patent Court practice develops and how the will be perceived by the industry. (Less)
- Abstract (Swedish)
- Denna uppsats syftar till att fastställa hur införandet av Enhetliga Patent och den Europeiska- och EU-patentdomstolen kommer att påverka läkemedelsindustrins val av patentansökningsförfarande när de ansöker om patent i Europa i framtiden. För att fastställa de förväntade effekterna av Enhetliga Patent på branschen har intervjuer med ett urval personer inom forskning- och utvecklingsföretag och en patentadvokat genomförts. Intervjuerna har visat en rad fördelar som förknippas med Enhetliga Patent, främst av ekonomisk karaktär, som en effekt av minskade översättningskrav och ökad centraliserad administration, men det är även sannolikt att vi kommer se att praxis så småningom kommer bli mer förutsägbar inom Europa. Många av de problem som... (More)
- Denna uppsats syftar till att fastställa hur införandet av Enhetliga Patent och den Europeiska- och EU-patentdomstolen kommer att påverka läkemedelsindustrins val av patentansökningsförfarande när de ansöker om patent i Europa i framtiden. För att fastställa de förväntade effekterna av Enhetliga Patent på branschen har intervjuer med ett urval personer inom forskning- och utvecklingsföretag och en patentadvokat genomförts. Intervjuerna har visat en rad fördelar som förknippas med Enhetliga Patent, främst av ekonomisk karaktär, som en effekt av minskade översättningskrav och ökad centraliserad administration, men det är även sannolikt att vi kommer se att praxis så småningom kommer bli mer förutsägbar inom Europa. Många av de problem som återstår att fastställa i avtalsförslagen har visat sig utgöra en stor nackdel för industrin eftersom det tillför en dimension av osäkerhet för patenthavare. Det faktum att Italien och Spanien valt att ställa sig utanför samarbetet med Enhetliga Patent är givetvis en stor nackdel för projektet och Europeiska Unionen som helhet. De slutsatser som kunnat dras är till följd av osäkerheterna och de nackdelar som redan påvisats med Enhetliga Patent att den bästa rekommendationen för patentsökande i framtiden är att fortsatt söka europeiska patent och att se hur praxis utvecklas och hur europeiska och EU-patentdomstolen kommer att fungera i praktiken. (Less)
Please use this url to cite or link to this publication:
http://lup.lub.lu.se/student-papers/record/2299989
- author
- Lerenius, Victor LU
- supervisor
- organization
- course
- HARH10 20112
- year
- 2012
- type
- M2 - Bachelor Degree
- subject
- keywords
- Patent application strategy, European and European Union Patent Court, Unitary Patent, Litigation, Patent protection, Intellectual property
- language
- English
- id
- 2299989
- date added to LUP
- 2012-01-24 08:33:08
- date last changed
- 2012-01-24 08:33:08
@misc{2299989,
abstract = {{This thesis aims to establish how the introduction of the Unitary Patent and the European and European Union Patent Court will affect the pharmaceutical industry’s choice of patent application route when applying for patents in Europe in the future. To establish the expected effect of the Unitary Patent on the industry interviews with a selection of professionals in the research and development industry, the public sector and a patent litigator have been carried out. The research and interviews has shown an array of advantages associated with the Unitary Patent, mainly of economic nature as an effect of reduced translation requirements and increased centralised administration but also we are likely to see that practice will eventually become more predictable within Europe. Many of the problems that remain to be established in the draft agreements have proven to be a major disadvantage to the Unitary Patent as it adds a dimension of uncertainty to the patent holder. The fact that Italy and Spain have chosen to opt out of the Unitary Patent project is unsurprisingly a major disadvantage to the project and the European Union as a whole. It has been concluded that the many uncertainties and the disadvantages already shown with the Unitary Patent the best recommendation to patent applicants in the future is to stay with the European patent or national patents to see how European and European Union Patent Court practice develops and how the will be perceived by the industry.}},
author = {{Lerenius, Victor}},
language = {{eng}},
note = {{Student Paper}},
title = {{Patent Application Strategy in Europe for the Pharmaceutical Industry - How should pharmaceutical companies’ patent application strategy change with the introduction of the Unitary Patent and the European and European Union Patent Court?}},
year = {{2012}},
}